Phaseline

Companies › Imbioray (Hangzhou) Biomedicine

Imbioray (Hangzhou) Biomedicine: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IBR854
Allogeneic anti-CD19 CAR-T cell therapy
–Phase 2Renal Cell Carcinoma (RCC)Dec 2026
IBR733 Cell Injection
Cell injection therapy
–Phase 1Acute Myeloid LeukemiaJul 2027
IBR900 cell injection
NK cell therapy
–Phase 1Relapsed/Refractory B-cell Non-Hodgkin LymphomaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07087158IBR854Phase 2Renal Cell Carcinoma (RCC)OncologyDec 2026
NCT06234904IBR733 Cell InjectionPhase 1Acute Myeloid LeukemiaOncologyJul 2027
NCT07073833IBR900 cell injectionPhase 1Relapsed/Refractory B-cell Non-Hodgkin LymphomaOncologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bio-Path Holdings Vividion Therapeutics GI Innovation Scancell Alpheus Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.